9-Aug-2021
NOX and US Govt Peak Cancer Agency Announce Collaboration
19-Jul-2019
NOX Announces AU$26 Million Funding Facility
26-Jun-2019
Conference Hears of Positive Interim Data from LuPIN Trial
6-Jun-2019
Noxopharm Corporate Presentation June 2019
30-May-2019
DARRT-1 Study Fully Enrolled
23-May-2019
Promising Data Leads to Expansion of LuPIN Trial
20-May-2019
LuPIN Trial Demonstrates High Rates of Response
2-May-2019
DARRT Treatment Has Lasting Disease Control at Six Months
29-Apr-2019
Veyonda and Immuno-Oncology Effect Explained
23-Apr-2019
Change in Noxopharm Limited Board Structure
16-Apr-2019
Idronoxil Confirmed as New Immuno-Oncology Drug
10-Apr-2019
Veyonda Chemotherapy Enhancement Program to be Expanded
21-Feb-2019
Noxopharm to expedite Veyonda Clinical Program
6-Feb-2019
FNN interview with Nox Chief Medical Officer on Interim Data
6-Feb-2019
Chief Medical Officer Discusses DARRT-1 trial interim results
6-Feb-2019
Veyonda and Radiotherapy Delivers Clinical Benefits
29-Jan-2019
Appendix 4C - quarterly report for the quarter ended December 31, 2018
11-Dec-2018
DARRT-1 study advancing on basis of positive clinical data
29-Nov-2018
NOX announces Positive Data from CEP-1 Study of Veyonda
21-Nov-2018
NOX 2018 AGM Presentations
13-Nov-2018
NOX to Present Clinical Data at COSA Annual Meeting
8-Nov-2018
Corporate Presentation
22-Oct-2018
NOX makes key executive appointment
4-Oct-2018
Noxopharm Releases Report on Key Progress of Subsidiary
27-Sep-2018
Annual Report to shareholders
24-Sep-2018
NOX Subsidiary Announces Important Drug Discovery
5-Sep-2018
NOX to support expanded LuPIN study
27-Aug-2018
Nyrada-Key progress with cholesterol-lowering drug candidate
20-Aug-2018
VEYONDA - Registered Trade Mark for NOX66
8-Aug-2018
Interim NOX66 Radiotherapy Clinical Data
9-Jul-2018
Release of DARRT-1 Preliminary Safety Data
5-Jul-2018
Pre-Clinical data confirms Radio-Enhancing potential
7-Jun-2018
Noxopharm Corporate Presentation for Public Briefing
5-Jun-2018
End-of-Study Clinical Data shows benefit of NOX66
22-May-2018
NOX to present at American Society of Clinical Oncology
18-May-2018
Noxopharm 2018 Mid-Year Investor Briefings
7-May-2018
NOX CEO interview updates the company's current R&D program
3-May-2018
NOX CEO interview on near complete NOX66 chemotherapy trial
27-Apr-2018
NOX CEO interview on Radiotherapy Clinical Programs
17-Apr-2018
St Vincent's Hospital study passes first milestone
5-Apr-2018
DARRT-1 Clinical Study commences
23-Mar-2018
NOX raises $10.8 M to advance clinical program
21-Mar-2018
Evidence of Abscopal Responses in Patients
12-Mar-2018
Corporate Presentation - Post Interim Clinical Data Release
9-Mar-2018
FNN Interview with Noxopharm CEO
6-Mar-2018
NOX Reports NOX66 Clinical Data
16-Feb-2018
NOX closes $4m capital raising for US subsidiary Nyrada Inc
17-Jan-2018
NOX receives FY17 R&D Tax Rebate
21-Dec-2017
EOY Guidance on 2018 NOX66 Clinical Development Strategy
6-Dec-2017
NOX Open Briefing Corporate Presentation
4-Dec-2017
Compassionate use of NOX66 in Patients
27-Nov-2017
AGM Presentations
20-Nov-2017
Promising Interim Clinical Data for NOX66
6-Nov-2017
Results of Meeting
6-Nov-2017
EGM Presentations
3-Nov-2017
UNSW collaboration confirms drug designed for stroke victims
30-Oct-2017
Appendix 4C - quarterly
23-Oct-2017
Update - General Meeting Agenda
19-Oct-2017
October 2017 Open Briefing Corporate Presentation
27-Sep-2017
Australian NOX66 - Radiotherapy Study Opens
25-Sep-2017
Establishment of Nyrada Inc.
12-Sep-2017
Positive Clinical Outcomes for NOX66 at ESMO Conference
4-Sep-2017
NOX CEO Interview explains recent Brain Cancer Announcement
29-Aug-2017
Important Brain Cancer Findings for NOX66 Program
24-Aug-2017
Reinstatement to Official Quotation
24-Aug-2017
Noxopharm raises $5.5 million to advance clinical program
23-Aug-2017
Suspension from Official Quotation
21-Aug-2017
Trading Halt Request
21-Aug-2017
Trading Halt
8-Aug-2017
NOX Corporate Presentation ahead of Conference
8-Aug-2017
Noxopharm's first 12 months since ASX listing
27-Jul-2017
NOX Research Report prepared by APP Securities
25-Jul-2017
CEO Interview with FNN - Singapore and HK Roadshow
25-Jul-2017
New Corporate Presentation
6-Jul-2017
Noxopharm provides update on NOX66 Clinical Trial Program
19-Jun-2017
Idronoxil data provides hope to treat secondary brain cancer
5-Jun-2017
NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
30-May-2017
New Corporate Presentation
29-May-2017
St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
24-May-2017
NOX makes strategic commitment to treatment of rare cancers
18-May-2017
Noxopharm Mid Year Investor Briefings
2-May-2017
Market Guidance for Next Six Months
27-Apr-2017
Appendix 4C - quarterly
10-Apr-2017
FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10-Apr-2017
NOX Files Patent Application on 'Smart' Idronoxil
27-Mar-2017
NOX and Monash Uni Collaboration Receives Federal Grant
16-Mar-2017
Noxopharm and UNSW combine on stroke project
10-Mar-2017
Gold Coast Qld Mid-Year Briefing Details
3-Mar-2017
NOX researching rare Abscopal Response
15-Feb-2017
Upcoming Events and Presentations
6-Feb-2017
February 2017 Newsletter
20-Jan-2017
Noxopharm CEO to present at ASX The CEO Sessions
23-Nov-2016
Breakthrough in Delivering Idronoxil into Brain
22-Nov-2016
Corporate Presentation Updated
22-Nov-2016
Corporate Presentation Providing Clinical Program Guidance
17-Nov-2016
Medical Advisors Appointed for Extensive Clinical Program
16-Nov-2016
Independent Investment Research Report November 2016
20-Oct-2016
Corporate Presentation
19-Sep-2016
APP Securities Company Research Report September 2016
20-Jul-2016
Noxopharm Limited Closes Oversubscribed IPO
27-Jun-2016
Noxopharm Press Release